Evidence map›Paper›PMID 42288902›Full record

Observational studyBMC palliative care2026

Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort study.

Catriona R Mayland, Michelle Collinson, Sam H Ahmedzai, Joseph Lucas, Jacqui Gath, Liz Darlison, Duneesha Defonseka, Barry Laird, Helena Stanley, Sarah Danson and 3 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in BMC palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Catriona R MaylandDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK. c.r.mayland@sheffield.ac.uk.
Michelle CollinsonClinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Sam H AhmedzaiDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Joseph LucasClinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Jacqui GathSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Liz DarlisonUniversity Hospitals of Leicester, Leicester, UK.
Duneesha DefonsekaSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Barry LairdInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Helena StanleySheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Sarah DansonDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Clare GardinerSchool of Allied Health Professionals, Nursing & Midwifery, University of Sheffield, Sheffield, UK.
Anna C BibbyBristol Academic Respiratory Unit, University of Bristol, Bristol, UK.
ASSESS-meso collaborative

Funding

Asthma and Lung UK APP11-1
6 · The paper itself

Abstract

backgroundPain associated with malignant mesothelioma can be complex. The natural course of pain over the disease trajectory is not well studied. The aim of this study was to explore the prevalence, severity, impact and clinical course of pain for people with mesothelioma over a 12-month period.

methodsA prospective observational study was conducted as a component of a larger national, multi-centre cohort study on mesothelioma - ASSESS-meso (A prospective obServational cohort Study collecting data on dEmographics, Symptoms and biomarkerS in people with mesothelioma) (ISRCTN: 61,861,764). Adults (> = 18 years) newly diagnosed with mesothelioma were recruited from out-patient clinics in 20 hospitals. Baseline demographic and clinical data were recorded. Frequency, severity and impact of pain, quality of life and mood were collected using Patient-Reported Outcome Measures (e.g., EORTC Quality of Life Questionnaire Core Questionnaire PALliative Cancer [QLQ-C15-PAL], Brief Pain Inventory [BPI]). Follow-up occurred 3-monthly for 12-months.

resultsAmong the 150 participants recruited, mean age was 72.4 years (SD 8.1), with 112 (74.7%) being men. Baseline assessments showed a greater proportion of participants were affected by dyspnoea compared with pain. Overall, twenty-one (14.0%) participants reported moderate or severe chest pain (defined as > = 40/100) although none were receiving strong opioids. Median pain duration was 14.1 weeks (IQR 10-24.1). At 9-12 months, quality of life was poorer in those reporting moderate or severe pain (mean overall QLQ-C15-PAL score 41.7 [SD = 20.4] vs. 71.6 [SD = 19.5]) and this pain interfered more with daily activities (mean BPI interference index, 29.1 [SD = 19.1] vs. 14.4 [SD = 14.5]). Sixty-six (44.0%) participants died during the 12-months follow-up period.

conclusionsParticipants reporting moderate or severe chest pain experienced poorer quality of life and none were receiving strong opioids. Given the limited prognosis, early identification of 'high risk' mesothelioma patients i.e. those who are most likely to have high symptom burden and poor prognosis, would help ensure timely input is given to implement pain management strategies. This includes Specialist Palliative Care guidance about opioid prescribing and interventional procedures. Future research should be directed towards the optimum ways to assess and improve breathlessness, without neglecting the smaller group of people who experience severe pain.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantPainAgedAged, 80 and overCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedPain MeasurementPrevalenceProspective StudiesQuality of LifeCohort studyMesotheliomaPainPalliative careQuality of life

Identifiers

PMID42288902
PMCPMC13491870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.